This inventor holds 2 USPTO granted patents. Top assignee: Hanmi Pharm. Co., Ltd.. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Kyungki-do, KR (2010)
- Gunpo-si, KR (2010)
Company Filing History:
Years Active: 2010
Title: Hyo-Jeong Bang: Innovator in Pharmaceutical Chemistry
Introduction
Hyo-Jeong Bang is a notable inventor based in Kyungki-do, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that are effective in treating various cancers. With a total of two patents to his name, his work has garnered attention in the scientific community.
Latest Patents
Hyo-Jeong Bang's latest patents include the development of 1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and a method for the preparation of 2'-deoxy-2′,2′-difluorocytidine. The first patent describes a derivative that can be easily purified through recrystallization, making it advantageous for large-scale production of gemcitabine. The second patent outlines an improved method for stereoselectively preparing 2'-deoxy-2′,2′-difluorocytidine, which is effective in treating various cancers such as non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer, and ovarian cancer.
Career Highlights
Hyo-Jeong Bang is currently associated with Hanmi Pharm. Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work focuses on creating compounds that can lead to more effective cancer treatments, showcasing his commitment to advancing medical science.
Collaborations
Hyo-Jeong Bang has collaborated with notable colleagues, including Jaeheon Lee and Moonsub Lee. These collaborations have likely contributed to the success of his research and patent developments.
Conclusion
Hyo-Jeong Bang is a prominent figure in pharmaceutical innovation, with patents that hold promise for cancer treatment. His contributions to the field reflect a dedication to improving healthcare through scientific advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
